anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Postparalysis facial synkinesis (PPFS) can develop in any facial palsy and is associated with significant functional and psychosocial consequences for affected patients. While the prevention of synkinesis especially after Bell's palsy has been well examined, much less evidence exists regarding the management of patients with already established synkinesis. Therefore, the purpose of this review is to summarize the available literature and to provide an overview of the current therapeutic options for facial palsy patients with established synkinesis. A systematic literature review was undertaken, following the Preferred Reporting Items of Systematic Reviews and Meta-analyses 2020 guidelines. MEDLINE via PubMed and Cochrane Library were searched using the following strategy: ([facial palsy] OR [facial paralysis] OR [facial paresis]) AND (synkinesis) AND ([management] OR [guidelines] OR [treatment]). The initial search yielded 201 articles of which 36 original papers and 2 meta-analyses met the criteria for inclusion. Overall, the included articles provided original outcome data on 1,408 patients. Articles were divided into the following treatment categories: chemodenervation (12 studies, 536 patients), facial therapy (5 studies, 206 patients), surgical (10 studies, 389 patients), and combination therapy (9 studies, 278 patients). Results are analyzed and discussed accordingly. Significant heterogeneity in study population and design, lack of control groups, differences in postoperative follow-up, as well as the use of a variety of subjective and objective assessment tools to quantify synkinesis prevent direct comparison between treatment modalities. To date, there is no consensus on how PPFS is best treated. The lack of comparative studies and standardized outcome reporting hinder our understanding of this complex condition. Until higher quality scientific evidence is available, it remains a challenge best approached in an interdisciplinary team. An individualized multimodal therapeutic concept consisting of facial therapy, chemodenervation, and surgery should be tailored to meet the specific needs of the patient.
An incisional hernia is a common complication of abdominal surgery with an incidence of 4-20%. Liver transplant patients represent a unique cohort of surgical patients with immediate immune suppression post-operatively. It is presumed that this immune suppression accompanied by significant co-morbidities have led to high incisional ventral hernia rates between 4.9%-34.3%.

A recent 2018 retrospective review of 1044 liver transplant patients identified age \>55, high BMI \> 25, and immediate rejection were significant risk factors contributing to herniation. However, previously concerning considerations including gender, diagnosis, diabetes, Child-Pugh score, MELD score, donor type, hepato-renal syndrome, varix bleeding, ascites, hepatic encephalopathy, ventilator use, spontaneous bacterial peritonitis (SBP), or bile leak were not identified as significant risk factors. Moreover, the mortality for chronic liver disease patients for elective hernia repair is 3.7% at 90 days and morbidity is 27%. Emergent hernia repair led to 10% 90-day mortality with 60% morbidity. The high incidence of herniation represents a common problem with significant morbidity and mortality post liver transplantation thereby requiring investigating a new preventative solution.

A recent retrospective trial in the colorectal literature identified an institutional incidence of incisional hernia for colorectal patients of 39.9%. They recognized two high-risk populations, obese, and non-obese with a combination of several secondary risk factors. A follow-up prospective cohort study separated all colorectal patients undergoing laparotomy to standardized running PDS closure versus those with BMI\>29 (the median in the prior study) and those BMI \<29 with \>=2 risk factors to include standard closure with an on-lay Ultrapro partially absorb-able mesh covering 3 cm adjacent to the incision placed with double down facial staples followed by a subcutaneous drain. The reported risk factors included BMI, smoking, serum creatinine, hemoglobin, serum albumin, COPD diabetes, immune suppression with steroids or radiation/chemotherapy, and previous midline laparotomy. The results revealed a decrease in the incisional hernia rate from 43.9% to 10% (P=0.0001). This study also concluded the treatment was cost effective and safe.
A home PAC team will care for patients in his/her home within 3 weeks after acute hospitalization. The patient will get a physical therapy (PT) or occupational therapy (OT) 1 to 6 session(s) per week.
This study aims to examine whether hypovitaminosis D was associated with cognitive impairment among chronic kidney patients with different level of albuminuria. This population-based cross-sectional study was conducted on elderly (over 60 years old) with urine albumin to creatinine ratio (UACR) ≥ 30 mg/g from 2011 to 2014 in the US National Health and Nutrition Examination Survey (NHANES). Cognitive function was assessed by the Consortium to Establish a Registry for Alzheimer's Disease Word List Learning (CERAD). Subjects were divided into 2 groups according to the absence or presence of cognitive impairment and a propensity score matching (PSM) was further conducted. The association was assessed with Spearman correlation and logistic regression analysis. The positive association of 25-hydroxyvitamin D3 (25(OH)D3) and cognitive score was presented. PSM analysis revealed that a higher level of 25(OH)D3 correlated to a better cognitive function in CKD patients with albuminuria, especially in patients with 30 mg/g ≤ UACR < 300 mg/g. This study indicated that a low 25(OH)D3 level was associated with poor cognitive performance, especially in patients with microalbuminuria. Thus, early diagnosis of vitamin D insufficiency and an effective intervention might be a useful therapeutic strategy to prevent cognitive decline in patients with the progression of renal dysfunction.
FIELD: medicine, cosmetics. SUBSTANCE: invention relates to agents designated for skin face care. Face cream removing toxins comprising oily phase, structure-forming emulsifying agents, BAD, triethanolamine, wetting additions, preserving agents, perfume composition and water involves additionally dimethicon and cyclomethicon, carbopol or carbomers, or SAKAP or SAKAP-R. Apricot oil or avocado oil, or peach oil, olive leaves oily extract, vitamin E, coneflower extract are used as BAD. Cream comprises isopropyl palmitate or isopropyl myristate as oily phase and centearyl alcohol and cetearete-20, methyl glucose sesquistearate and methylglucete-20, glycerol or propylene glycol, allantoin, bronopol or bronitrol, para- hydroxybenzoic acid methyl and propyl esters or Katon or Germaben as structure-forming emulsifying agents. Cream shows anti-inflammatory effect, eliminates toxins, wets skin effectively and exhibits antiseptic and stimulating action. EFFECT: valuable medicinal and cosmetic properties of cream. 2 tbl
Cell culture obtained from meristematic cells of Dendrobiumplant and Phalaenopsisplant, comprises phenylpropanoid (greater than 0.1 wt.%) and hydrosoluble polysaccharides (greater than wt.%). An independent claim is included for the meristematic cells preparation comprising the cell culture and glycerol, where the cell culture is free from the liquid culture medium and has a weight/volume ratio of 5:95-50:50, preferably 20:50. ACTIVITY : Anabolic; Antiinflammatory; Dermatological; Gastrointestinal-Gen.; Antimicrobial; Respiratory-Gen.; Ophthalmological; Immunosuppressive. MECHANISM OF ACTION : Hyaluronidase inhibitor; Collagenase inhibitor. The hyaluronidase inhibiting activity of the cell culture (comprising Phalaenopsis aphrodite(800 mu g/ml)) was tested in extracellular matrix. The result showed that percentage inhibition rate of the cell culture was 87.5.
This is an prospective open multi-center randomized phase II study of standard dose azacytidine with or without the addition of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q). Seventy-two patients, eligible for treatment with azacytidine (Intermedium/INT-2 and High-risk MDS and AML with 20-30 % marrow blasts according to label) will be included.

Azacytidine will be given in a modified standard dose, azacytidine 5+2 (75 mg/m2/ d subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacytidine 75 mg/m2/ d for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles. Cycle interval may be prolonged if toxicity according to predefined criteria occurs. Patients will be randomized to azacytidine (Arm A) or azacytidine + lenalidomide (Arm B). The initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacytidine cycle and leaving the last week before start of next azacytidine cycle free. The dose should be increased to 20 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. The total study period is 24 weeks + additional weeks caused by prolonged cycle interval. Patients, who following a response may be eligible for allo-SCT may exit the study after cycle 3, 4 or 5 and then be subject to end-of-study assessment. Patients who at start of treatment, or any time during study have a neutrophil count \<0,5 x 109/l will be treated with Granulocyte-ColonyStimulatingFactor (G-CSF).
PURPOSE:To obtain an anti-AIDS viral agent containing an extract obtained from pinecones of Pinus pentaphylla Mayr var. himekomatsu Makino with an aqueous alkali as an active ingredient. CONSTITUTION:An anti-AIDS viral agent containing polysaccharides, especially an effective KS-7 component contained in an extract obtained from pinecones [preferably Pinus thunbergii Parl. (Japanese black pine), Pinus densiflora Sieb. et Zucc. (Japanese red pine), especially Pinus pentaphylla Mayr var. himekomatus Makino] with an aqueous alkali as an active ingredient. T cells in blood are infected with AIDS viruses to induce immunological inhibition resulting in death. The KS-7 has not only anti-AIDS viral action but also immunological activity of remarkably activating monocytes derived fro human peripheral blood or polymorphonuclear leukocytes, etc. absent in other vegetable polysaccharides. Treatment is effectively carried out by using the KS-7 alone or in combination with other therapies or remedies (azidothymidine, suramin, etc.).
This study is a matched pair design, single-arm study with the following two treatments: current standard of care (SOC) and the LuViva study device. After undergoing the LuViva test, all study subjects will first undergo the SOC (i.e., nominal) colposcopy, with the colposcopist noting on the case report form (CRF), locations of lesions with colposcopy impression of CIN1+. Then the colposcopist will employ enhanced colposcopy measures that include the use on Lugol's solution and green/blue filters. The colposcopist will note on the CRF any additional lesions that became evident as a result of these enhanced measures, regardless of colposcopic impression. Biopsies of these lesions will be taken. Biopsies identified using SOC practices will be placed in vials labeled "SOC Samples". Biopsies identified using enhanced practices will be placed in vials labeled "Additional Samples". The colposcopist will then take a biopsy from any quadrant at the squamocolumnar junction (SCJ) in which a lesion was not observed. These biopsies will be placed in the vial labeled "Additional Samples". Once all colposcopy procedures are completed, biopsies of lesions collected, and biopsies of any non-lesion identified quadrants collected, an ECC, if indicated, will be collected. If an ECC would have been taken per SOC practices, it will be placed in a vial labeled "SOC ECC". ECCs collected per enhanced procedures will be placed in a vial labeled "Additional ECC". The study is a matched pair design because all subjects are tested with the LuViva device, and all will undergo both the nominal (minimal) colposcopy and biopsy treatment pursuant to ASCCP Guidelines as well as enhanced colposcopy and biopsy. By analyzing all biopsy specimens from SOC procedures and enhanced procedures, it can be determined 1) Whether enhanced procedures can be justified when the LuViva test indicates High-risk by the increase in detection of CIN2+ and 2) That when LuViva indicates Low-risk, that enhanced procedures (in the absence of a LuViva High-risk result) are not the reason for increased detection of CIN2+. Subjects will be enrolled during their normally scheduled colposcopy visit and will be recruited from the pool of patients that are referred to colposcopy based on the ASCCP Guidelines published in April 2020. The total number of enrolled female subjects pooled across all clinical sites combined will not exceed 500 in order to target an evaluable cohort of approximately 400 women.
A stratified randomization method was used to determine intervention, placebo and control groups. It was ensured that the nurses were evenly distributed to the groups according to their age, working year and baseline fatigue scores. A computer-generated (https://www.randomizer.org/) sorting was used to allocate the groups homogeneously.

The intervention groups received five sessions of auricular acupuncture with semi-permanent needles and seeds once a week. Semi-permanent needles and seeds placed in nurses' ear acupuncture points stayed for one week. In the sessions in the following weeks, semi-permanent needles and seeds were replaced with new ones. Nurses were reminded to remove the semi-permanent needle and seed tapes 24 hours before the scheduled session. They are also instructed to remove it beforehand if there is any discomfort, itching or any sign of allergy. Placement of the semi-permanent needles and seed tapes took approximately five minutes per session. Before each session for the semi-permanent needle group, the ears of the participants were cleaned with a 70% alcohol wipe and sterile, fine-caliber, disposable semi-permanent needles were used. A similar application was made to the seed group and they were asked to apply pressure on the bands three times a day, 15 times each time.

These were placed unilaterally on five specific points in the ear (ShenMen, sympathetic, liver, kidney, lung) by a certified specialist in acupuncture using the National Acupuncture Detoxification Association (NADA) protocol. Since the body or organs have an emotional component and can be adversely affected by excessive and prolonged emotions, these ear points were chosen to facilitate the release of negative/toxic emotions from the organs. This process was thought to help the treated participant return to balance and increase energy and well-being by giving a feeling of calm instead of stress and anxiety. Shen men (TF4) and Sympathetic (AH6a) points can regulate the sympathetic and parasympathetic nervous systems to effectively reduce patient tension and anxiety. In addition, the TF4 point reduces anxiety, while the AH6a point calms excessive sympathetic activity. Both of these points help increase parasympathetic activation by balancing the sympathetic/parasympathetic branches of the autonomic nervous system. Low mood and lethargy are improved by stimulating the liver (CO12). Kidney point (CO10) is a point that has a strengthening effect by relieving mental weakness, fatigue and headaches and stimulating kidney functions. Combining these ear acupuncture points can increase the energy and blood flow of the organs, thereby relieving the patient's fatigue.

Data were collected at baseline and at the end of the intervention (week 5) using the Chalder Fatigue Scale, Subjective Vitality Scale, and Well-being Scale.
Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
<P>PROBLEM TO BE SOLVED: To provide a medical image transmission apparatus capable of transmitting a plurality of medical images to a medical image output device in an appropriate order based on incidental information.  <P>SOLUTION: CPU (central processing unit) 10 of the medical image transmission apparatus, at every time of capturing medical image data outputted from a modality 3, stores the data in a capture image table 72, recognizes the medical image data as characters to obtain the incidental information and sequentially store it in the capture image table 72. Then, the CPU rearranges the capture image table 72 so that the image numbers in the incidental information become an ascending order and updates it. The CPU 10 allocates and rearranges the medical image data in frame positions of respective pages of output image data 74 in the order stored in the updated capture image table 72. If a printer of a transmission printer name 66 ia a face-up feed type, the CPU inverses the transmission order of the respective pages of the output image data 74 and transmits them to the printer.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D3 (cholecalciferol). Vitamin D3 must be metabolically activated in the liver and the kidney before it is fully active as a regulator of calcium and phosphorus metabolism at target tissues. The initial transformation of vitamin D3 is catalyzed by a vitamin D3-25-hydroxylase enzyme (25-OHase) present in the liver, and the product of this reaction is 25 hydroxyvitamin D3 [25-(OH)D3]. Hydroxylation of 25-(OH)D3 occurs in the mitochondria of kidney tissue, activated by the renal 25-hydroxyvitamin D3-1 alpha-hydroxylase (alpha-OHase), to produce 1,25-(OH)2D3 (calcitriol), the active form of vitamin D3. Endogenous synthesis and catabolism of calcitriol, as well as physiological control mechanisms affecting these processes, play a critical role regulating the serum level of calcitriol. Physiological daily production is normally 0.5 to 1.0 mcg and is somewhat higher during periods of increased bone synthesis (eg, growth or pregnancy).
Sand is an irritant to people and animals. The application of the sand remover powder mixture consisting of 40% montmorillonite and 60% Maranta arundinacea and rubbed/wiped removes sand from effected areas of skin and hair on humans and animals better together than in their individual natural state. In some embodiments sand remover powder can contain fragrance. Sand remover powder and rubbing/wiping can be used to remove residue from hair. Sand remover powder can be used as a body powder. Some sand remover powder embodiments can be ingested.
Participants in group 2 will receive MWM technique treatment 3 times a week for 4 weeks. The patient should lie face down with a pillow over the knee and the physiotherapist should stand on the contralateral side for the application. The physiotherapist passes the belt around the waist to the patient's tibia edge. The knee is stabilized with one hand while the leg is supported with the other hand. The knee is moved medially without applying too much force through the belt and the patient is asked to stretch. If there is no pain, the movement is indicated. If pain occurs during the movement, the same procedure is performed for the lateral side by changing the position. It is important that the arch remains horizontal and does not cause rotation of the hip. The movement will be repeated 3 times at the point where there is no pain.
For each participant in the transcutaneous nerve stimulation (TENS) group, standard rehabilitation (SR) in addition a TENS stimulator (BioTENS, Skylark Device \& Systems Co., Ltd) was applied with 0.2-ms pulses at 100 Hz in the constant mode within the subject's sensory level without muscle contraction via (5 × 3.5 cm) electrodes attached to the motor points of the tibia anterior (TA) and quadriceps muscles on the affected lower extremity. For the TENS group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
Appropriate fibrosis is required to prevent subsequent adverse remodeling and heart failure post myocardial infarction (MI), and cardiac fibroblasts (CFs) play a critical role during the process. Carbonic anhydrase 3 (CAR3) is an important mediator in multiple biological processes besides its CO2 hydration activity; however, the role and underlying mechanism of CAR3 on cardiac repair post MI injury remains unknown. Here, we found that CAR3 expression was up-regulated in cardiac tissue in infarct area at the reparative phase of MI, with a peak at 7 days post MI. The upregulation was detected mainly on fibroblast instead of cardiomyocyte, and primary cardiac fibroblasts treated with TGF-β1 recaptured our observation. While CAR3 deficiency leads to weakened collagen density, enlarged infarct size and aggravated cardiac dysfunction post-MI. In fibroblast, we observed that CAR3 deficiency restrains collagen synthesis, cell migration and gel contraction of cardiac fibroblasts, whereas overexpression of CAR3 in CFs improves wound healing and cardiac fibroblast activation. Mechanistically, CAR3 stabilizes Smad7 protein via modulating its acetylation, which dampens phosphorylation of Smad2 and Smad3, thus inhibiting fibroblast transformation. In contrast, inhibition of Smad7 acetylation with C646 blunts CAR3 deficiency induced suppression of fibroblast activation and impaired cardiac healing. Our data demonstrate a protective role of CAR3 in cardiac wound repair post MI via promoting fibroblasts activation through Smad7-TGF-β/Smad2/3 signaling pathway.
The invention belongs to the field of Chinese medicines, denomination of invention is a kind of pharmaceutical composition for the treatment of endometriosis and preparation method thereof, this pharmaceutical composition is made up of the raw material of following weight portion: Radix Angelicae Sinensis? 1 ~ 5, Semen Persicae? 1 ~ 5, Pollen Typhae? 1 ~ 5, Myrrha? 1 ~ 5, Cortex Moutan? 1 ~ 5, Radix Achyranthis Rubrofuscae 1 ~ 5.This pharmaceutical composition adopts pharmaceutical methods conventional in pharmacy to be prepared into tablet, pill, hard capsule, granule, oral liquid.This pharmaceutical composition can be used for the medicine preparing treatment endometriosis and pelvic inflammatory disease.
If tolerability is demonstrated in the 78mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
PURPOSE: An intermediate compound for preparing urocanic acid and a method for preparing the same are provided to enable easy purification and reaction termination and to prepare a compound used in various industries. CONSTITUTION: An intermediate compound is denoted by chemical formula 4. The intermediate compound is used as an intermediate for preparing urocanic acid. A method for preparing the intermediate comprises a step of reacting a compound of chemical formula 2 and a compound of chemical formula 3 under the presence of a base and metal catalyst. The metal catalyst is a palladium catalyst including dichlorobis(triphenylphosphine)palladium or tetrakis(triphenylphosphine)palladium. The base is triethyl amine or potassium carbonate.